DAXOR CORP (DXR) Stock Fundamental Analysis
USA - NASDAQ:DXR - US2394671034 - Common Stock
13 USD
+0.21 (+1.64%)
We assign a fundamental rating of 3 out of 10 to DXR. DXR was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While DXR seems to be doing ok healthwise, there are quite some concerns on its profitability. DXR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
DXR had positive earnings in the past year.
In the past year DXR had a positive cash flow from operations.
Of the past 5 years DXR 4 years were profitable.
DXR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.00%, DXR belongs to the top of the industry, outperforming 81.38% of the companies in the same industry.
With a decent Return On Equity value of 5.00%, DXR is doing good in the industry, outperforming 78.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5% | ||
| ROE | 5% | ||
| ROIC | N/A |
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DXR's Profit Margin of 2710.84% is amongst the best of the industry. DXR outperforms 99.47% of its industry peers.
DXR's Profit Margin has declined in the last couple of years.
DXR does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2710.84% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.69%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DXR has more shares outstanding than it did 1 year ago.
DXR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DXR has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 142.37 indicates that DXR is not in any danger for bankruptcy at the moment.
DXR has a better Altman-Z score (142.37) than 100.00% of its industry peers.
DXR has a debt to FCF ratio of 0.19. This is a very positive value and a sign of high solvency as it would only need 0.19 years to pay back of all of its debts.
DXR's Debt to FCF ratio of 0.19 is amongst the best of the industry. DXR outperforms 93.09% of its industry peers.
DXR has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
DXR has a Debt to Equity ratio of 0.01. This is in the better half of the industry: DXR outperforms 71.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.19 | ||
| Altman-Z | 142.37 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
DXR has a Current Ratio of 0.04. This is a bad value and indicates that DXR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.04, DXR is doing worse than 98.40% of the companies in the same industry.
DXR has a Quick Ratio of 0.04. This is a bad value and indicates that DXR is not financially healthy enough and could expect problems in meeting its short term obligations.
DXR's Quick ratio of 0.04 is on the low side compared to the rest of the industry. DXR is outperformed by 98.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.04 | ||
| Quick Ratio | 0.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 24.24% over the past year.
The earnings per share for DXR have been decreasing by -54.66% on average. This is quite bad
Looking at the last year, DXR shows a very negative growth in Revenue. The Revenue has decreased by -56.97% in the last year.
DXR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.63% yearly.
EPS 1Y (TTM)24.24%
EPS 3Y-54.66%
EPS 5YN/A
EPS Q2Q%77.42%
Revenue 1Y (TTM)-56.97%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-74.37%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 31.71, the valuation of DXR can be described as expensive.
Based on the Price/Earnings ratio, DXR is valued a bit cheaper than 73.40% of the companies in the same industry.
DXR is valuated rather expensively when we compare the Price/Earnings ratio to 25.07, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.71 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, DXR is valued a bit cheaper than the industry average as 73.94% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.58 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
DXR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:DXR (11/20/2025, 8:00:01 PM)
13
+0.21 (+1.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners2.01%
Inst Owner Change-7.22%
Ins Owners5.42%
Ins Owner Change0.08%
Market Cap64.74M
Revenue(TTM)66.40K
Net Income(TTM)1.80M
Analysts80
Price Target23.97 (84.38%)
Short Float %0.33%
Short Ratio1.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.71 | ||
| Fwd PE | N/A | ||
| P/S | 975 | ||
| P/FCF | 46.58 | ||
| P/OCF | 46.58 | ||
| P/B | 1.81 | ||
| P/tB | 1.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.41
EY3.15%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.28
FCFY2.15%
OCF(TTM)0.28
OCFY2.15%
SpS0.01
BVpS7.17
TBVpS7.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5% | ||
| ROE | 5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2710.84% | ||
| GM | N/A | ||
| FCFM | 2093.37% |
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.69%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.19 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 77.22% | ||
| Current Ratio | 0.04 | ||
| Quick Ratio | 0.04 | ||
| Altman-Z | 142.37 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.24%
EPS 3Y-54.66%
EPS 5YN/A
EPS Q2Q%77.42%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-56.97%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-74.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y144.13%
FCF growth 3YN/A
FCF growth 5Y-60.47%
OCF growth 1Y144.13%
OCF growth 3YN/A
OCF growth 5Y-60.47%
DAXOR CORP / DXR FAQ
Can you provide the ChartMill fundamental rating for DAXOR CORP?
ChartMill assigns a fundamental rating of 3 / 10 to DXR.
What is the valuation status of DAXOR CORP (DXR) stock?
ChartMill assigns a valuation rating of 2 / 10 to DAXOR CORP (DXR). This can be considered as Overvalued.
Can you provide the profitability details for DAXOR CORP?
DAXOR CORP (DXR) has a profitability rating of 3 / 10.
Can you provide the dividend sustainability for DXR stock?
The dividend rating of DAXOR CORP (DXR) is 0 / 10 and the dividend payout ratio is 0%.